 "Medical illustration : Pills of all kinds, shapes and colours")
Ahmedabad-based pharma major Zydus Cadila registered a net profit of Rs 389 crore for the fourth quarter of the fiscal 2015-16, up 11% on the back of a 7% rise in total income from operations during the quarter on a year-on-year basis. Consolidated total income from operations during the quarter stood at Rs 2,449 crore.
During the fiscal year, the company posted a net profit of Rs 1,523 crore for the fiscal 2015-16, up by 32% from Rs 1,151 crore, on a consolidated basis. Consolidated total income from operations of the company grew by 14% during the year to Rs 9,838 crore from Rs 8,651 crore registered last year.
The company's formulations business in the US was the largest contributor to consolidated revenues and the key driver of overall growth. During the year, the formulations in the US business grew by 19% and crossed $600-million mark in sales for the first time. Strengthening its regulatory pipeline, the company filed 30 ANDAs during the year with the USFDA, taking the cumulative filings to 269. The company received 10 ANDA approvals during the year, taking the total to 103 product approvals.
The company's formulations business in India grew by 11% during the year on the back of launch of more than 40 new products, including line extensions. The company's formulations business in emerging markets grew by 17%.
